Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Status:
Completed

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

The purpose of the study is to see if daily and twice daily administration of BIIB021 is tolerated in patients with advanced solid tumors.

Phase 1

Biogen